Navigation Links
ResearchDx Launches Contract Diagnostics Organization (CDO)
Date:2/22/2011

IRVINE, Calif., Feb. 22, 2011 /PRNewswire/ -- ResearchDx announced today the official launch of the first-ever Contract Diagnostics Organization or CDO.

Recent FDA initiatives, such as the Critical Path Initiative and the Drug-Diagnostic Co-Development Concept Paper, have spurred biopharmaceutical companies' interest in biomarker research for the purpose of developing companion diagnostics. The traditional Contract Research Organization (CRO), which has focused on clinical trials for pharmaceutical products, cannot meet the need for both an in-depth knowledge of the diagnostics industry and the ability to run diagnostic tests in a clinical laboratory. Conversely, Diagnostics companies lack the ability to perform clinical testing and have an incentive to steer diagnostic development toward their existing products' technology platforms. However, ResearchDx, as a CDO, provides all of these services in an integrated, technology-independent manner that stays focused on their customers' business objectives.

"At ResearchDx, we take contract R&D for diagnostics to the next generation," states co-founder Philip Cotter.  "Our partners trust ResearchDx to provide everything they need to develop a diagnostic product, and that we make their business objectives our priority."

Dr. Philip Cotter and Dr. Mat Moore, the founders of ResearchDx, have a passion for the advancement of personalized medicine. With their team's extensive experience in managing clinical laboratories, designing and managing clinical research, and navigating the complex regulatory environment specific to diagnostics, they saw the opportunity to fill an unmet need for partnership with the biopharmaceutical and diagnostics industries.  In founding the first-ever CDO, they have achieved their vision to help biopharmaceutical companies overcome the barriers to developing diagnostic products.

About ResearchDx

ResearchDx is a Contract Diagnostics Organization (CDO) for the biopharmaceutical and diagnostic industries. The company provides integrated, flexible services for the diagnostic development process – from initial assay concepts and discovery through clinical research to regulatory approval.   ResearchDx's service areas include clinical research, clinical laboratory services, diagnostic manufacturing, and consulting.

CONTACT:  Philip Cotter, +1-510-332-0477, for ResearchDx


'/>"/>
SOURCE ResearchDx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PreXion Launches New Faster, Lower Radiation PreXion3D Elite Cone Beam Imaging System
2. Zimmer Launches PathFinder NXT™ Minimally Invasive Pedicle Screw System
3. Success Factors and Failure Points in Biopharmaceutical Product Launches
4. Stryker Orthopaedics Launches Its First iPad™ Apps for Surgeons, Available Through Apples App Store(SM)
5. HIMSS11: Ingenious Med Launches Billing and Data Capture App for iPhone, iPod touch and iPad
6. Boston Scientific Launches PROMUS® Element™ and TAXUS® Element™ Stent Systems in India
7. Brainlab Launches Refreshed Website
8. Cayenne Medical, Inc. Launches AperFix® II
9. ForteBio Launches New Octet® RED96 System and Dip and Read™ Protein L Biosensor
10. Mylan Launches First Generic Version of Vfend® Tablets
11. PARI Respiratory Launches New Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... 2016 TARE (Transarterial Radio-embolization) ... Savings and Overall Decreased Use of Hospital ... international specialist healthcare company, has today announced the ... Meeting of ISPOR (International Society for Pharmacoeconomics and ... (HCC) using yttrium-90 glass microspheres is associated with ...
(Date:5/25/2016)... FDA 510(k) clearance covers ... for urological and surgical applications Mauna ... Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) platform, ... US with the 12 th 510(k) clearance ... This new FDA clearance covers Confocal Miniprobes indicated ...
(Date:5/25/2016)... , Germany and GERMANTOWN, ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... licensing and co-development agreement with Therawis Diagnostics GmbH to develop ... be to develop and market PITX2 as a marker to ... high-risk breast cancer patients. "We are pleased to ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 27, 2016 , ... An educational campaign aimed at everyone ... courtesy of awareness-driven celebrities and thought leaders. It also provides insight to the ... leaders such as Bioness. , As patients feel increasingly concerned about the ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... Aimed at ... human interest stories, which come courtesy of leaders in the nursing and health care ... from leading advocates and associations—namely Abilene Christian University. , As the nursing industry ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways to cook a ... (NHDSC) suggests that Americans prefer their dogs straight off the grill. Of the 90 ... their favorite way to cook a hot dog, far outpacing other cooking methods such ...
(Date:5/26/2016)... Atlanta, Georgia (PRWEB) , ... May 26, 2016 ... ... a certificate in intellectual property (IP) to its specialty academic programs. , Answering ... joins the college’s existing certificate programs in health law, and environmental and land ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... a significant negative impact on long-term patient survival, reports a team of UPMC ... online this week in the Journal of Thoracic and Cardiovascular Surgery, provide critical ...
Breaking Medicine News(10 mins):